• This study is a retrospective comparison of the results in 25 low-dose, intra-arterial streptokinase and 12 low-dose intra-arterial urokinase infusions for thromboembolic disease. Intra-arterial streptokinase was successful in 50% of infusions and was marked by significant abnormalities in the coagulation criteria. There was a high incidence of major and minor bleeding (48% overall), which could be attributed to systemic effects of the drug. Urokinase was successful in 100% of infusions, and showed no significant effects on systemic coagulation criteria. There were also fewer complications during urokinase infusion. The average pharmacy cost for a course of intra-arterial streptokinase was $165, while urokinase cost $1142. Despite the significant difference in expense, the increased efficacy and safety of urokinase make it the preferred agent for intra-arterial infusion. Theoretical reasons for the increased effectiveness of urokinase are discussed.
(Arch Surg 1986;121:769-773)
Belkin M, Belkin B, Bucknam CA, Straub JJ, Lowe R. Intra-arterial Fibrinolytic Therapy: Efficacy of Streptokinase vs Urokinase. Arch Surg. 1986;121(7):769–773. doi:10.1001/archsurg.1986.01400070035007
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.